Sarepta Therapeutics Inc (NASDAQ:SRPT) shares jumped 26.29% to $17.55 as a research firm cited several factors supporting the approval of eteplirsen. Sarepta Therapeutics Inc (NASDAQ:SRPT) shares retreated 2.06% in after-hours trading but investors are hopeful that the anticipation for an accelerated approval for eteplirsen, an RNA-based therapeutic drug designed treatment of some...
Looking to trade small cap biotech news? Here's our roundup of what to keep an eye on this week in the space. It’s going to be a big week for a number of companies in the small cap biotech space. Here’s a look at the three that have the biggest...
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) could pick up some upside this week if the agency approves its lead schizophrenia candidate. Here's why. The coming week is set to be a big one in the development stage biotech space, with a number of companies scheduled to report what could be game changing data. The FDA...
Premarket on Wednesday, April 20, 2016, development stage biotech company MediciNova, Inc. (NASDAQ:MNOV) reported interim data from its ongoing trial of MN-166 – its lead amyotrophic lateral sclerosis (ALS) candidate. The company lost strength on Tuesday, but could well pick up a market capitalization boost across Wednesday’s session in...
At the beginning of April, 2016, Minnesota based biotech Vascular Solutions, Inc. (NASDAQ:VASC) reported that it was withdrawing and recalling a large number of its lead product, its Guardian® II Hemostasis Valves, from the market. The recall came on the back of findings that suggested the product could leak,...